MediWound Ltd.

MDWD Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.85 0.36 −2.95%
Market cap
$157.6M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.05
Beneish M
−3.69
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 4 3
ROE
0.00% (63.49%) 0.00% (75.42%)
ROA
(24.36%) (29.90%) (35.04%) (29.06%)
ROIC
0.00% 0.00% 0.00% (6,551.77%)
Return on Tangible Assets
(34.34%) (45.14%) (51.40%) (44.09%)
Average Days of Receivables
105.29 58.78 69.27 107.47
Free Cash Flow per Share
(1.69) (1.90) (1.95) (2.21)
Free Cash Flow
(18.60) (21.63) (25.13) (28.53)
Capital Expenditures
(3.86) (5.50) (6.37) (6.39)
Other line items
Cash ROIC
(16.86%) (22.15%) (28.89%) (40.19%)
Accounts Receivable Turnover
3.69 3.75 3.65 2.31
Accounts Payable Turnover
2.93 2.12 1.88 1.49
Inventory Turnover
4.59 4.04 2.79 2.52
Average Days of Payables
182.15 203.69 232.30 277.54
Days of Inventory on Hand
94.28 109.01 149.64 149.84
Tax Rate
0.01 0.01 0.01 0.01
Research and Development Expense of Revenue
61.28% 84.44% 114.78% 160.41%
Selling, General and Administrative Expense of Revenue
69.73% 83.81% 101.51% 126.65%
Share Based Compensation of Revenue
15.61% 18.33% 20.08% 23.61%
Interest Coverage
— (1.65) — (2.27)
Operating CF/Net income
0.72 0.68 0.72 1.10
Depreciation/Fixed assets
0.09 0.10 0.09 0.09
Capex/Depreciation
(2.46) (2.96) (3.39) (3.39)
Revenue per Share
1.90 1.49 1.12 0.92
Operating CF per Share
(1.34) (1.42) (1.46) (1.72)
Capex per Share
(0.35) (0.48) (0.49) (0.50)
Capex to Sales
0.18 0.32 0.44 0.54

Fold the line items

Columns are period end dates